Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

Fig. 1

Postulated mechanisms between association of chemotherapy-induced neutropenia at 1-month mark (CIN-1-month) and overall survival: (a) Firstly, one may postulate that patients with a high tumor burden could have a high baseline neutrophil count; making it less likely to experience CIN-1-month; (b) Secondly, since the drug incorporates into the tumor, for patients with a high tumor burden, it is possible that that the standard dosage of the drug may not be enough to exert myelotoxicity; and c) Finally, individuals experiencing different degrees of neutropenia may have different pharmacokinetics of TAS-102 and its metabolites

Back to article page